Theravance Biopharma (TBPH)
Commercializes YUPELRI with Viatris while winding down ampreloxetine.
Something off on this page? Send us feedback.
Commercial value centers on YUPELRI, a once-daily nebulized COPD maintenance therapy co-developed with Viatris. Viatris leads commercialization, Theravance shares US economics, and the company is being acquired by Zymeworks after an ampreloxetine study miss and a narrower strategic review.
Commercial focus is concentrated in YUPELRI, a nebulized maintenance therapy for COPD. Viatris leads commercialization, while Theravance co-promotes in the US and receives economics from Viatris-led work outside the US, including China-region rights.
Ampreloxetine has shifted from active pipeline program to residual monetization asset after a late-stage study miss. TRELEGY now matters through retained milestone potential, not as a product sold by Theravance.
Execution has centered on narrowing the portfolio, monetizing royalty interests, and preserving YUPELRI cash-flow participation. The business depends on Viatris collaboration performance, respiratory-market competition, settled generic-entry timing for YUPELRI, and completion of the pending Zymeworks acquisition.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $387.7M · Total debt $38.6M · Total assets $469.8M · Shareholders' equity $289.7M
- Revenue
- $20.7M
- Operating income
- −$604.0K
- Net income
- −$5.9M
No dividends on record.
| Institutions186 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 93.58% | 48.24M shares | |
| Insiders12 holders · as of Aug 24, 2026 | 6.19% | 3.19M shares | |
| Strategic holders1 holder · as of Sep 20, 2022 | 0.00% | 1 shares | |
| Otherremainder | ≈ 0.23% | 117.4K shares |
51.55M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Woodford Equity Income FundInstitution | 20.55% | 10.59M | 13Gfiled Feb 14, 2019 ↗ |
Madison Avenue Partners, LPInstitution | 17.87% | 9.21M | 13Fas of Jun 30, 2026 |
Weiss Asset Management LPInstitution | 14.46% | 7.46M | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.85% | 4.56M | 13Fas of Jun 30, 2026 |
Newtyn Management, LLCInstitution | 6.66% | 3.43M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 1, 2026 | Eli Samaha | 10 percent owner | −37,799 | $17.00 |
| Jun 30, 2026 | Eli Samaha | 10 percent owner | −25,027 | $17.13 |
| Jun 29, 2026 | Eli Samaha | 10 percent owner | −273,871 | $17.23 |
| Jun 15, 2026 | Rhonda Farnum | officer: SVP, COMM & MEDICAL AFFAIRS | −13,314 | $16.39 |
| Mar 16, 2026 | Rhonda Farnum | officer: SVP, COMM & MEDICAL AFFAIRS | −31,067 | $13.96 |
- Merck
Direct nebulized COPD maintenance pressure through Ohtuvayre
- GSK (ADR)
COPD biologic and TRELEGY-linked respiratory overlap
- AstraZeneca (ADR)
Triple-therapy pressure through Breztri and Symbicort
- Sanofi (ADR)
Dupixent exposure in eosinophilic COPD add-on care
- Regeneron
Dupixent co-owner in COPD biologic add-on therapy
- Novartis (ADR)
Peripheral asthma triple-therapy pressure through Enerzair
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Theravance Biopharma | $17.08 | +0.29% | $884.7M | 16.8 | 6.0 | 8.5 | −20.9% |
| Merck | $151.14 | −0.33% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| GSK (ADR) | $50.50 | +0.15% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| AstraZeneca (ADR) | $163.48 | +1.13% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Sanofi (ADR) | $44.52 | +0.12% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Median | 24.4 | 15.2 | 4.9 | +5.7% |